targetId,strataId,cohortId,cohortType,name
101,1,101000011,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with Age < 60
102,1,102000011,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with Age < 60
103,1,103000011,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with Age < 60
104,1,104000011,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with Age < 60
105,1,105000011,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with Age < 60
106,1,106000011,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with Age < 60
101,2,101000021,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with Age 60 - 69
102,2,102000021,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with Age 60 - 69
103,2,103000021,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with Age 60 - 69
104,2,104000021,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with Age 60 - 69
105,2,105000021,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with Age 60 - 69
106,2,106000021,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with Age 60 - 69
101,3,101000031,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with Age 70 - 79
102,3,102000031,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with Age 70 - 79
103,3,103000031,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with Age 70 - 79
104,3,104000031,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with Age 70 - 79
105,3,105000031,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with Age 70 - 79
106,3,106000031,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with Age 70 - 79
101,4,101000041,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with Age >= 80
102,4,102000041,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with Age >= 80
103,4,103000041,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with Age >= 80
104,4,104000041,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with Age >= 80
105,4,105000041,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with Age >= 80
106,4,106000041,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with Age >= 80
101,301,101003011,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Performance Status ECOG=0
102,301,102003011,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Performance Status ECOG=0
103,301,103003011,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Performance Status ECOG=0
104,301,104003011,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Performance Status ECOG=0
105,301,105003011,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Performance Status ECOG=0
106,301,106003011,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Performance Status ECOG=0
101,302,101003021,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Performance Status ECOG=1
102,302,102003021,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Performance Status ECOG=1
103,302,103003021,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Performance Status ECOG=1
104,302,104003021,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Performance Status ECOG=1
105,302,105003021,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Performance Status ECOG=1
106,302,106003021,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Performance Status ECOG=1
101,303,101003031,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Performance Status ECOG=2+
102,303,102003031,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Performance Status ECOG=2+
103,303,103003031,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Performance Status ECOG=2+
104,303,104003031,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Performance Status ECOG=2+
105,303,105003031,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Performance Status ECOG=2+
106,303,106003031,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Performance Status ECOG=2+
101,304,101003041,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Prevalent obesity S11
102,304,102003041,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Prevalent obesity S11
103,304,103003041,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Prevalent obesity S11
104,304,104003041,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Prevalent obesity S11
105,304,105003041,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Prevalent obesity S11
106,304,106003041,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Prevalent obesity S11
101,305,101003051,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Prevalent hypertension S12
102,305,102003051,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Prevalent hypertension S12
103,305,103003051,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Prevalent hypertension S12
104,305,104003051,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Prevalent hypertension S12
105,305,105003051,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Prevalent hypertension S12
106,305,106003051,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Prevalent hypertension S12
101,306,101003061,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Total Cardiovascular Disease Event S13
102,306,102003061,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Total Cardiovascular Disease Event S13
103,306,103003061,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Total Cardiovascular Disease Event S13
104,306,104003061,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Total Cardiovascular Disease Event S13
105,306,105003061,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Total Cardiovascular Disease Event S13
106,306,106003061,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Total Cardiovascular Disease Event S13
101,307,101003071,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
102,307,102003071,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
103,307,103003071,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
104,307,104003071,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
105,307,105003071,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
106,307,106003071,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
101,308,101003081,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
102,308,102003081,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
103,308,103003081,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
104,308,104003081,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
105,308,105003081,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
106,308,106003081,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
101,309,101003091,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Anxiety S17
102,309,102003091,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Anxiety S17
103,309,103003091,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Anxiety S17
104,309,104003091,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Anxiety S17
105,309,105003091,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Anxiety S17
106,309,106003091,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Anxiety S17
101,310,101003101,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
102,310,102003101,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
103,310,103003101,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
104,310,104003101,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
105,310,105003101,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
106,310,106003101,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
101,311,101003111,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Family History of PCa S22
102,311,102003111,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Family History of PCa S22
103,311,103003111,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Family History of PCa S22
104,311,104003111,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Family History of PCa S22
105,311,105003111,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Family History of PCa S22
106,311,106003111,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Family History of PCa S22
101,312,101003121,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Physical Therapy S23
102,312,102003121,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Physical Therapy S23
103,312,103003121,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Physical Therapy S23
104,312,104003121,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Physical Therapy S23
105,312,105003121,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Physical Therapy S23
106,312,106003121,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Physical Therapy S23
101,313,101003131,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
102,313,102003131,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
103,313,103003131,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
104,313,104003131,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
105,313,105003131,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
106,313,106003131,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
101,314,101003141,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
102,314,102003141,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
103,314,103003141,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
104,314,104003141,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
105,314,105003141,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
106,314,106003141,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
101,315,101003151,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
102,315,102003151,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
103,315,103003151,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
104,315,104003151,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
105,315,105003151,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
106,315,106003151,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
101,316,101003161,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Metastasis recurrent RT-FINAL
102,316,102003161,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Metastasis recurrent RT-FINAL
103,316,103003161,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Metastasis recurrent RT-FINAL
104,316,104003161,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Metastasis recurrent RT-FINAL
105,316,105003161,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Metastasis recurrent RT-FINAL
106,316,106003161,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Metastasis recurrent RT-FINAL
101,317,101003171,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Metastasis recurrent RP-FINAL
102,317,102003171,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Metastasis recurrent RP-FINAL
103,317,103003171,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Metastasis recurrent RP-FINAL
104,317,104003171,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Metastasis recurrent RP-FINAL
105,317,105003171,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Metastasis recurrent RP-FINAL
106,317,106003171,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Metastasis recurrent RP-FINAL
101,318,101003181,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] MRI of prostate FINAL
102,318,102003181,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] MRI of prostate FINAL
103,318,103003181,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] MRI of prostate FINAL
104,318,104003181,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] MRI of prostate FINAL
105,318,105003181,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] MRI of prostate FINAL
106,318,106003181,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] MRI of prostate FINAL
101,319,101003191,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Bone scan S30
102,319,102003191,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Bone scan S30
103,319,103003191,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Bone scan S30
104,319,104003191,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Bone scan S30
105,319,105003191,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Bone scan S30
106,319,106003191,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Bone scan S30
101,320,101003201,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Abdominal CT scan
102,320,102003201,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Abdominal CT scan
103,320,103003201,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Abdominal CT scan
104,320,104003201,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Abdominal CT scan
105,320,105003201,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Abdominal CT scan
106,320,106003201,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Abdominal CT scan
101,321,101003211,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] CT scan of whole body S32
102,321,102003211,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] CT scan of whole body S32
103,321,103003211,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] CT scan of whole body S32
104,321,104003211,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] CT scan of whole body S32
105,321,105003211,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] CT scan of whole body S32
106,321,106003211,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] CT scan of whole body S32
101,322,101003221,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] PET-CT imaging FINAL
102,322,102003221,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] PET-CT imaging FINAL
103,322,103003221,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] PET-CT imaging FINAL
104,322,104003221,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] PET-CT imaging FINAL
105,322,105003221,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] PET-CT imaging FINAL
106,322,106003221,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] PET-CT imaging FINAL
101,323,101003231,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER S7] PSA>20
102,323,102003231,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER S7] PSA>20
103,323,103003231,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER S7] PSA>20
104,323,104003231,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER S7] PSA>20
105,323,105003231,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER S7] PSA>20
106,323,106003231,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER S7] PSA>20
101,324,101003241,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER S8] PSA<10
102,324,102003241,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER S8] PSA<10
103,324,103003241,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER S8] PSA<10
104,324,104003241,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER S8] PSA<10
105,324,105003241,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER S8] PSA<10
106,324,106003241,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER S8] PSA<10
101,325,101003251,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER S9] PSA 10-20
102,325,102003251,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER S9] PSA 10-20
103,325,103003251,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER S9] PSA 10-20
104,325,104003251,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER S9] PSA 10-20
105,325,105003251,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER S9] PSA 10-20
106,325,106003251,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER S9] PSA 10-20
101,326,101003261,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER V2.0] Earliest Gleason Grade 1
102,326,102003261,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER V2.0] Earliest Gleason Grade 1
103,326,103003261,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER V2.0] Earliest Gleason Grade 1
104,326,104003261,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER V2.0] Earliest Gleason Grade 1
105,326,105003261,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER V2.0] Earliest Gleason Grade 1
106,326,106003261,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER V2.0] Earliest Gleason Grade 1
101,327,101003271,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER V2.0] Earliest Gleason Grade 2 - 3
102,327,102003271,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER V2.0] Earliest Gleason Grade 2 - 3
103,327,103003271,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER V2.0] Earliest Gleason Grade 2 - 3
104,327,104003271,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER V2.0] Earliest Gleason Grade 2 - 3
105,327,105003271,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER V2.0] Earliest Gleason Grade 2 - 3
106,327,106003271,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER V2.0] Earliest Gleason Grade 2 - 3
101,328,101003281,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER V2.0] Earliest Gleason Grade 4
102,328,102003281,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER V2.0] Earliest Gleason Grade 4
103,328,103003281,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER V2.0] Earliest Gleason Grade 4
104,328,104003281,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER V2.0] Earliest Gleason Grade 4
105,328,105003281,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER V2.0] Earliest Gleason Grade 4
106,328,106003281,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER V2.0] Earliest Gleason Grade 4
101,329,101003291,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER V2.0] Earliest Gleason Grade 5
102,329,102003291,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER V2.0] Earliest Gleason Grade 5
103,329,103003291,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER V2.0] Earliest Gleason Grade 5
104,329,104003291,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER V2.0] Earliest Gleason Grade 5
105,329,105003291,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER V2.0] Earliest Gleason Grade 5
106,329,106003291,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER V2.0] Earliest Gleason Grade 5
101,330,101003301,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER S1] High-Risk
102,330,102003301,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER S1] High-Risk
103,330,103003301,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER S1] High-Risk
104,330,104003301,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER S1] High-Risk
105,330,105003301,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER S1] High-Risk
106,330,106003301,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER S1] High-Risk
101,331,101003311,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER S2] Low-Risk
102,331,102003311,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER S2] Low-Risk
103,331,103003311,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER S2] Low-Risk
104,331,104003311,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER S2] Low-Risk
105,331,105003311,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER S2] Low-Risk
106,331,106003311,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER S2] Low-Risk
101,332,101003321,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER S3] Intermediate-Risk
102,332,102003321,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER S3] Intermediate-Risk
103,332,103003321,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER S3] Intermediate-Risk
104,332,104003321,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER S3] Intermediate-Risk
105,332,105003321,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER S3] Intermediate-Risk
106,332,106003321,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER S3] Intermediate-Risk
101,333,101003331,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] MRI of prostate S59
102,333,102003331,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] MRI of prostate S59
103,333,103003331,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] MRI of prostate S59
104,333,104003331,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] MRI of prostate S59
105,333,105003331,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] MRI of prostate S59
106,333,106003331,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] MRI of prostate S59
101,334,101003341,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Bone scan FINAL
102,334,102003341,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Bone scan FINAL
103,334,103003341,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Bone scan FINAL
104,334,104003341,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Bone scan FINAL
105,334,105003341,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Bone scan FINAL
106,334,106003341,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Bone scan FINAL
101,335,101003351,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
102,335,102003351,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
103,335,103003351,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
104,335,104003351,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
105,335,105003351,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
106,335,106003351,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
101,336,101003361,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [Pioneer v2.0] PSA higher than 20
102,336,102003361,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [Pioneer v2.0] PSA higher than 20
103,336,103003361,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [Pioneer v2.0] PSA higher than 20
104,336,104003361,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [Pioneer v2.0] PSA higher than 20
105,336,105003361,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [Pioneer v2.0] PSA higher than 20
106,336,106003361,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [Pioneer v2.0] PSA higher than 20
101,337,101003371,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [Pioneer v2.0] PSA lower than 10
102,337,102003371,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [Pioneer v2.0] PSA lower than 10
103,337,103003371,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [Pioneer v2.0] PSA lower than 10
104,337,104003371,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [Pioneer v2.0] PSA lower than 10
105,337,105003371,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [Pioneer v2.0] PSA lower than 10
106,337,106003371,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [Pioneer v2.0] PSA lower than 10
101,338,101003381,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
102,338,102003381,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
103,338,103003381,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
104,338,104003381,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
105,338,105003381,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
106,338,106003381,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
101,339,101003391,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Fatigue
102,339,102003391,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Fatigue
103,339,103003391,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Fatigue
104,339,104003391,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Fatigue
105,339,105003391,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Fatigue
106,339,106003391,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Fatigue
101,340,101003401,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Diarrhea
102,340,102003401,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Diarrhea
103,340,103003401,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Diarrhea
104,340,104003401,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Diarrhea
105,340,105003401,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Diarrhea
106,340,106003401,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Diarrhea
101,341,101003411,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with FDA AESI Immune thrombocytopenia (ITP) events
102,341,102003411,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with FDA AESI Immune thrombocytopenia (ITP) events
103,341,103003411,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with FDA AESI Immune thrombocytopenia (ITP) events
104,341,104003411,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with FDA AESI Immune thrombocytopenia (ITP) events
105,341,105003411,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with FDA AESI Immune thrombocytopenia (ITP) events
106,341,106003411,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with FDA AESI Immune thrombocytopenia (ITP) events
101,342,101003421,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with {PIONEER 2.0] Neutropenia
102,342,102003421,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with {PIONEER 2.0] Neutropenia
103,342,103003421,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with {PIONEER 2.0] Neutropenia
104,342,104003421,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with {PIONEER 2.0] Neutropenia
105,342,105003421,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with {PIONEER 2.0] Neutropenia
106,342,106003421,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with {PIONEER 2.0] Neutropenia
101,343,101003431,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Convulsion
102,343,102003431,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Convulsion
103,343,103003431,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Convulsion
104,343,104003431,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Convulsion
105,343,105003431,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Convulsion
106,343,106003431,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Convulsion
101,344,101003441,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [Pioneer 2.0] Acute myocardial infarction
102,344,102003441,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [Pioneer 2.0] Acute myocardial infarction
103,344,103003441,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [Pioneer 2.0] Acute myocardial infarction
104,344,104003441,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [Pioneer 2.0] Acute myocardial infarction
105,344,105003441,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [Pioneer 2.0] Acute myocardial infarction
106,344,106003441,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [Pioneer 2.0] Acute myocardial infarction
101,345,101003451,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Constipation
102,345,102003451,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Constipation
103,345,103003451,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Constipation
104,345,104003451,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Constipation
105,345,105003451,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Constipation
106,345,106003451,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Constipation
101,346,101003461,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Hypokalemia
102,346,102003461,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Hypokalemia
103,346,103003461,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Hypokalemia
104,346,104003461,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Hypokalemia
105,346,105003461,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Hypokalemia
106,346,106003461,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Hypokalemia
101,347,101003471,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Index date 2016
102,347,102003471,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Index date 2016
103,347,103003471,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Index date 2016
104,347,104003471,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Index date 2016
105,347,105003471,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Index date 2016
106,347,106003471,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Index date 2016
101,348,101003481,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Index date 2017
102,348,102003481,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Index date 2017
103,348,103003481,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Index date 2017
104,348,104003481,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Index date 2017
105,348,105003481,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Index date 2017
106,348,106003481,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Index date 2017
101,349,101003491,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Index date 2018
102,349,102003491,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Index date 2018
103,349,103003491,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Index date 2018
104,349,104003491,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Index date 2018
105,349,105003491,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Index date 2018
106,349,106003491,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Index date 2018
101,350,101003501,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Index date 2019
102,350,102003501,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Index date 2019
103,350,103003501,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Index date 2019
104,350,104003501,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Index date 2019
105,350,105003501,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Index date 2019
106,350,106003501,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Index date 2019
101,351,101003511,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Index date 2020
102,351,102003511,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Index date 2020
103,351,103003511,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Index date 2020
104,351,104003511,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Index date 2020
105,351,105003511,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Index date 2020
106,351,106003511,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Index date 2020
101,352,101003521,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Index year 2021
102,352,102003521,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Index year 2021
103,352,103003521,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Index year 2021
104,352,104003521,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Index year 2021
105,352,105003521,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Index year 2021
106,352,106003521,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Index year 2021
101,353,101003531,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with [PIONEER 2.0] Index year 2022
102,353,102003531,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with [PIONEER 2.0] Index year 2022
103,353,103003531,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with [PIONEER 2.0] Index year 2022
104,353,104003531,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with [PIONEER 2.0] Index year 2022
105,353,105003531,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with [PIONEER 2.0] Index year 2022
106,353,106003531,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with [PIONEER 2.0] Index year 2022
101,354,101003541,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
102,354,102003541,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
103,354,103003541,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
104,354,104003541,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
105,354,105003541,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
106,354,106003541,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
101,355,101003551,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
102,355,102003551,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
103,355,103003551,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
104,355,104003551,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
105,355,105003551,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
106,355,106003551,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
101,356,101003561,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
102,356,102003561,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
103,356,103003561,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
104,356,104003561,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
105,356,105003561,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
106,356,106003561,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
101,357,101003571,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
102,357,102003571,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
103,357,103003571,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
104,357,104003571,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
105,357,105003571,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
106,357,106003571,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
101,358,101003581,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA
102,358,102003581,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA
103,358,103003581,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA
104,358,104003581,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA
105,358,105003581,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA
106,358,106003581,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA
101,359,101003591,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
102,359,102003591,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
103,359,103003591,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
104,359,104003591,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
105,359,105003591,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
106,359,106003591,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
101,360,101003601,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
102,360,102003601,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
103,360,103003601,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
104,360,104003601,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
105,360,105003601,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
106,360,106003601,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
101,361,101003611,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
102,361,102003611,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
103,361,103003611,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
104,361,104003611,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
105,361,105003611,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
106,361,106003611,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
101,362,101003621,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
102,362,102003621,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
103,362,103003621,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
104,362,104003621,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
105,362,105003621,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
106,362,106003621,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
101,363,101003631,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO
102,363,102003631,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO
103,363,103003631,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO
104,363,104003631,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO
105,363,105003631,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO
106,363,106003631,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO
101,364,101003641,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
102,364,102003641,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
103,364,103003641,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
104,364,104003641,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
105,364,105003641,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
106,364,106003641,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
101,365,101003651,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
102,365,102003651,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
103,365,103003651,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
104,365,104003651,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
105,365,105003651,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
106,365,106003651,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
101,366,101003661,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
102,366,102003661,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
103,366,103003661,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
104,366,104003661,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
105,366,105003661,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
106,366,106003661,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
101,367,101003671,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
102,367,102003671,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
103,367,103003671,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
104,367,104003671,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
105,367,105003671,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
106,367,106003671,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
101,368,101003681,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
102,368,102003681,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
103,368,103003681,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
104,368,104003681,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
105,368,105003681,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
106,368,106003681,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
101,369,101003691,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
102,369,102003691,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
103,369,103003691,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
104,369,104003691,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
105,369,105003691,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
106,369,106003691,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
101,370,101003701,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + lutetium PSMA
102,370,102003701,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + lutetium PSMA
103,370,103003701,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + lutetium PSMA
104,370,104003701,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + lutetium PSMA
105,370,105003701,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + lutetium PSMA
106,370,106003701,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + lutetium PSMA
101,371,101003711,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT +Radium 223
102,371,102003711,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT +Radium 223
103,371,103003711,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT +Radium 223
104,371,104003711,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT +Radium 223
105,371,105003711,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT +Radium 223
106,371,106003711,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT +Radium 223
101,372,101003721,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
102,372,102003721,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
103,372,103003721,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
104,372,104003721,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
105,372,105003721,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
106,372,106003721,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
101,373,101003731,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + olaparib
102,373,102003731,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + olaparib
103,373,103003731,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + olaparib
104,373,104003731,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + olaparib
105,373,105003731,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + olaparib
106,373,106003731,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + olaparib
101,374,101003741,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + rucaparib
102,374,102003741,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + rucaparib
103,374,103003741,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + rucaparib
104,374,104003741,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + rucaparib
105,374,105003741,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + rucaparib
106,374,106003741,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + rucaparib
101,375,101003751,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + immunotherapy
102,375,102003751,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + immunotherapy
103,375,103003751,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + immunotherapy
104,375,104003751,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + immunotherapy
105,375,105003751,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + immunotherapy
106,375,106003751,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + immunotherapy
101,376,101003761,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + sipuleucel-T
102,376,102003761,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + sipuleucel-T
103,376,103003761,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + sipuleucel-T
104,376,104003761,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + sipuleucel-T
105,376,105003761,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + sipuleucel-T
106,376,106003761,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + sipuleucel-T
101,377,101003771,TwS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + pembrolizumab
102,377,102003771,TwS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + pembrolizumab
103,377,103003771,TwS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL with REVIEW [PIONEER 2.0] ADT + pembrolizumab
104,377,104003771,TwS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + pembrolizumab
105,377,105003771,TwS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL with REVIEW [PIONEER 2.0] ADT + pembrolizumab
106,377,106003771,TwS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL with REVIEW [PIONEER 2.0] ADT + pembrolizumab
101,301,101003012,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Performance Status ECOG=0
102,301,102003012,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Performance Status ECOG=0
103,301,103003012,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Performance Status ECOG=0
104,301,104003012,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Performance Status ECOG=0
105,301,105003012,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Performance Status ECOG=0
106,301,106003012,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Performance Status ECOG=0
101,302,101003022,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Performance Status ECOG=1
102,302,102003022,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Performance Status ECOG=1
103,302,103003022,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Performance Status ECOG=1
104,302,104003022,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Performance Status ECOG=1
105,302,105003022,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Performance Status ECOG=1
106,302,106003022,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Performance Status ECOG=1
101,303,101003032,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Performance Status ECOG=2+
102,303,102003032,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Performance Status ECOG=2+
103,303,103003032,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Performance Status ECOG=2+
104,303,104003032,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Performance Status ECOG=2+
105,303,105003032,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Performance Status ECOG=2+
106,303,106003032,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Performance Status ECOG=2+
101,304,101003042,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Prevalent obesity S11
102,304,102003042,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Prevalent obesity S11
103,304,103003042,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Prevalent obesity S11
104,304,104003042,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Prevalent obesity S11
105,304,105003042,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Prevalent obesity S11
106,304,106003042,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Prevalent obesity S11
101,305,101003052,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Prevalent hypertension S12
102,305,102003052,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Prevalent hypertension S12
103,305,103003052,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Prevalent hypertension S12
104,305,104003052,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Prevalent hypertension S12
105,305,105003052,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Prevalent hypertension S12
106,305,106003052,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Prevalent hypertension S12
101,306,101003062,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Total Cardiovascular Disease Event S13
102,306,102003062,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Total Cardiovascular Disease Event S13
103,306,103003062,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Total Cardiovascular Disease Event S13
104,306,104003062,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Total Cardiovascular Disease Event S13
105,306,105003062,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Total Cardiovascular Disease Event S13
106,306,106003062,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Total Cardiovascular Disease Event S13
101,307,101003072,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
102,307,102003072,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
103,307,103003072,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
104,307,104003072,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
105,307,105003072,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
106,307,106003072,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Prevalent Type 2 Diabetes Mellitus S15
101,308,101003082,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
102,308,102003082,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
103,308,103003082,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
104,308,104003082,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
105,308,105003082,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
106,308,106003082,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events S16
101,309,101003092,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Anxiety S17
102,309,102003092,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Anxiety S17
103,309,103003092,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Anxiety S17
104,309,104003092,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Anxiety S17
105,309,105003092,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Anxiety S17
106,309,106003092,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Anxiety S17
101,310,101003102,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
102,310,102003102,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
103,310,103003102,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
104,310,104003102,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
105,310,105003102,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
106,310,106003102,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Prevalent Asthma or Chronic obstructive pulmonary disease (COPD) S18
101,311,101003112,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Family History of PCa S22
102,311,102003112,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Family History of PCa S22
103,311,103003112,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Family History of PCa S22
104,311,104003112,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Family History of PCa S22
105,311,105003112,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Family History of PCa S22
106,311,106003112,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Family History of PCa S22
101,312,101003122,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Physical Therapy S23
102,312,102003122,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Physical Therapy S23
103,312,103003122,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Physical Therapy S23
104,312,104003122,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Physical Therapy S23
105,312,105003122,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Physical Therapy S23
106,312,106003122,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Physical Therapy S23
101,313,101003132,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
102,313,102003132,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
103,313,103003132,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
104,313,104003132,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
105,313,105003132,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
106,313,106003132,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0]Â Strata Cohort S24 Metastasis stage M1a
101,314,101003142,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
102,314,102003142,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
103,314,103003142,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
104,314,104003142,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
105,314,105003142,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
106,314,106003142,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Strata Cohort S25 Metastasis stage M1b
101,315,101003152,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
102,315,102003152,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
103,315,103003152,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
104,315,104003152,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
105,315,105003152,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
106,315,106003152,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0]Â Strata Cohort S26 Metastasis stage M1c
101,316,101003162,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Metastasis recurrent RT-FINAL
102,316,102003162,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Metastasis recurrent RT-FINAL
103,316,103003162,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Metastasis recurrent RT-FINAL
104,316,104003162,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Metastasis recurrent RT-FINAL
105,316,105003162,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Metastasis recurrent RT-FINAL
106,316,106003162,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Metastasis recurrent RT-FINAL
101,317,101003172,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Metastasis recurrent RP-FINAL
102,317,102003172,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Metastasis recurrent RP-FINAL
103,317,103003172,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Metastasis recurrent RP-FINAL
104,317,104003172,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Metastasis recurrent RP-FINAL
105,317,105003172,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Metastasis recurrent RP-FINAL
106,317,106003172,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Metastasis recurrent RP-FINAL
101,318,101003182,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] MRI of prostate FINAL
102,318,102003182,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] MRI of prostate FINAL
103,318,103003182,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] MRI of prostate FINAL
104,318,104003182,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] MRI of prostate FINAL
105,318,105003182,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] MRI of prostate FINAL
106,318,106003182,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] MRI of prostate FINAL
101,319,101003192,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Bone scan S30
102,319,102003192,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Bone scan S30
103,319,103003192,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Bone scan S30
104,319,104003192,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Bone scan S30
105,319,105003192,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Bone scan S30
106,319,106003192,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Bone scan S30
101,320,101003202,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Abdominal CT scan
102,320,102003202,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Abdominal CT scan
103,320,103003202,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Abdominal CT scan
104,320,104003202,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Abdominal CT scan
105,320,105003202,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Abdominal CT scan
106,320,106003202,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Abdominal CT scan
101,321,101003212,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] CT scan of whole body S32
102,321,102003212,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] CT scan of whole body S32
103,321,103003212,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] CT scan of whole body S32
104,321,104003212,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] CT scan of whole body S32
105,321,105003212,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] CT scan of whole body S32
106,321,106003212,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] CT scan of whole body S32
101,322,101003222,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] PET-CT imaging FINAL
102,322,102003222,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] PET-CT imaging FINAL
103,322,103003222,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] PET-CT imaging FINAL
104,322,104003222,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] PET-CT imaging FINAL
105,322,105003222,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] PET-CT imaging FINAL
106,322,106003222,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] PET-CT imaging FINAL
101,323,101003232,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER S7] PSA>20
102,323,102003232,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER S7] PSA>20
103,323,103003232,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER S7] PSA>20
104,323,104003232,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER S7] PSA>20
105,323,105003232,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER S7] PSA>20
106,323,106003232,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER S7] PSA>20
101,324,101003242,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER S8] PSA<10
102,324,102003242,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER S8] PSA<10
103,324,103003242,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER S8] PSA<10
104,324,104003242,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER S8] PSA<10
105,324,105003242,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER S8] PSA<10
106,324,106003242,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER S8] PSA<10
101,325,101003252,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER S9] PSA 10-20
102,325,102003252,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER S9] PSA 10-20
103,325,103003252,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER S9] PSA 10-20
104,325,104003252,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER S9] PSA 10-20
105,325,105003252,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER S9] PSA 10-20
106,325,106003252,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER S9] PSA 10-20
101,326,101003262,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER V2.0] Earliest Gleason Grade 1
102,326,102003262,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER V2.0] Earliest Gleason Grade 1
103,326,103003262,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER V2.0] Earliest Gleason Grade 1
104,326,104003262,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER V2.0] Earliest Gleason Grade 1
105,326,105003262,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER V2.0] Earliest Gleason Grade 1
106,326,106003262,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER V2.0] Earliest Gleason Grade 1
101,327,101003272,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER V2.0] Earliest Gleason Grade 2 - 3
102,327,102003272,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER V2.0] Earliest Gleason Grade 2 - 3
103,327,103003272,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER V2.0] Earliest Gleason Grade 2 - 3
104,327,104003272,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER V2.0] Earliest Gleason Grade 2 - 3
105,327,105003272,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER V2.0] Earliest Gleason Grade 2 - 3
106,327,106003272,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER V2.0] Earliest Gleason Grade 2 - 3
101,328,101003282,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER V2.0] Earliest Gleason Grade 4
102,328,102003282,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER V2.0] Earliest Gleason Grade 4
103,328,103003282,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER V2.0] Earliest Gleason Grade 4
104,328,104003282,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER V2.0] Earliest Gleason Grade 4
105,328,105003282,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER V2.0] Earliest Gleason Grade 4
106,328,106003282,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER V2.0] Earliest Gleason Grade 4
101,329,101003292,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER V2.0] Earliest Gleason Grade 5
102,329,102003292,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER V2.0] Earliest Gleason Grade 5
103,329,103003292,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER V2.0] Earliest Gleason Grade 5
104,329,104003292,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER V2.0] Earliest Gleason Grade 5
105,329,105003292,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER V2.0] Earliest Gleason Grade 5
106,329,106003292,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER V2.0] Earliest Gleason Grade 5
101,330,101003302,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER S1] High-Risk
102,330,102003302,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER S1] High-Risk
103,330,103003302,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER S1] High-Risk
104,330,104003302,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER S1] High-Risk
105,330,105003302,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER S1] High-Risk
106,330,106003302,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER S1] High-Risk
101,331,101003312,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER S2] Low-Risk
102,331,102003312,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER S2] Low-Risk
103,331,103003312,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER S2] Low-Risk
104,331,104003312,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER S2] Low-Risk
105,331,105003312,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER S2] Low-Risk
106,331,106003312,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER S2] Low-Risk
101,332,101003322,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER S3] Intermediate-Risk
102,332,102003322,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER S3] Intermediate-Risk
103,332,103003322,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER S3] Intermediate-Risk
104,332,104003322,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER S3] Intermediate-Risk
105,332,105003322,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER S3] Intermediate-Risk
106,332,106003322,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER S3] Intermediate-Risk
101,333,101003332,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] MRI of prostate S59
102,333,102003332,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] MRI of prostate S59
103,333,103003332,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] MRI of prostate S59
104,333,104003332,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] MRI of prostate S59
105,333,105003332,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] MRI of prostate S59
106,333,106003332,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] MRI of prostate S59
101,334,101003342,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Bone scan FINAL
102,334,102003342,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Bone scan FINAL
103,334,103003342,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Bone scan FINAL
104,334,104003342,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Bone scan FINAL
105,334,105003342,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Bone scan FINAL
106,334,106003342,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Bone scan FINAL
101,335,101003352,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
102,335,102003352,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
103,335,103003352,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
104,335,104003352,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
105,335,105003352,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
106,335,106003352,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] CT thorax_abdomen_pelvis OR full body MRI FINAL
101,336,101003362,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [Pioneer v2.0] PSA higher than 20
102,336,102003362,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [Pioneer v2.0] PSA higher than 20
103,336,103003362,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [Pioneer v2.0] PSA higher than 20
104,336,104003362,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [Pioneer v2.0] PSA higher than 20
105,336,105003362,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [Pioneer v2.0] PSA higher than 20
106,336,106003362,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [Pioneer v2.0] PSA higher than 20
101,337,101003372,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [Pioneer v2.0] PSA lower than 10
102,337,102003372,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [Pioneer v2.0] PSA lower than 10
103,337,103003372,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [Pioneer v2.0] PSA lower than 10
104,337,104003372,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [Pioneer v2.0] PSA lower than 10
105,337,105003372,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [Pioneer v2.0] PSA lower than 10
106,337,106003372,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [Pioneer v2.0] PSA lower than 10
101,338,101003382,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
102,338,102003382,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
103,338,103003382,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
104,338,104003382,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
105,338,105003382,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
106,338,106003382,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [Pioneer v2.0] PSA between 10 - 20 at index
101,339,101003392,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Fatigue
102,339,102003392,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Fatigue
103,339,103003392,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Fatigue
104,339,104003392,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Fatigue
105,339,105003392,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Fatigue
106,339,106003392,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Fatigue
101,340,101003402,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Diarrhea
102,340,102003402,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Diarrhea
103,340,103003402,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Diarrhea
104,340,104003402,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Diarrhea
105,340,105003402,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Diarrhea
106,340,106003402,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Diarrhea
101,341,101003412,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without FDA AESI Immune thrombocytopenia (ITP) events
102,341,102003412,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without FDA AESI Immune thrombocytopenia (ITP) events
103,341,103003412,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without FDA AESI Immune thrombocytopenia (ITP) events
104,341,104003412,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without FDA AESI Immune thrombocytopenia (ITP) events
105,341,105003412,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without FDA AESI Immune thrombocytopenia (ITP) events
106,341,106003412,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without FDA AESI Immune thrombocytopenia (ITP) events
101,342,101003422,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without {PIONEER 2.0] Neutropenia
102,342,102003422,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without {PIONEER 2.0] Neutropenia
103,342,103003422,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without {PIONEER 2.0] Neutropenia
104,342,104003422,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without {PIONEER 2.0] Neutropenia
105,342,105003422,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without {PIONEER 2.0] Neutropenia
106,342,106003422,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without {PIONEER 2.0] Neutropenia
101,343,101003432,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Convulsion
102,343,102003432,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Convulsion
103,343,103003432,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Convulsion
104,343,104003432,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Convulsion
105,343,105003432,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Convulsion
106,343,106003432,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Convulsion
101,344,101003442,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [Pioneer 2.0] Acute myocardial infarction
102,344,102003442,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [Pioneer 2.0] Acute myocardial infarction
103,344,103003442,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [Pioneer 2.0] Acute myocardial infarction
104,344,104003442,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [Pioneer 2.0] Acute myocardial infarction
105,344,105003442,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [Pioneer 2.0] Acute myocardial infarction
106,344,106003442,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [Pioneer 2.0] Acute myocardial infarction
101,345,101003452,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Constipation
102,345,102003452,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Constipation
103,345,103003452,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Constipation
104,345,104003452,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Constipation
105,345,105003452,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Constipation
106,345,106003452,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Constipation
101,346,101003462,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Hypokalemia
102,346,102003462,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Hypokalemia
103,346,103003462,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Hypokalemia
104,346,104003462,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Hypokalemia
105,346,105003462,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Hypokalemia
106,346,106003462,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Hypokalemia
101,347,101003472,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Index date 2016
102,347,102003472,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Index date 2016
103,347,103003472,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Index date 2016
104,347,104003472,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Index date 2016
105,347,105003472,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Index date 2016
106,347,106003472,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Index date 2016
101,348,101003482,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Index date 2017
102,348,102003482,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Index date 2017
103,348,103003482,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Index date 2017
104,348,104003482,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Index date 2017
105,348,105003482,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Index date 2017
106,348,106003482,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Index date 2017
101,349,101003492,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Index date 2018
102,349,102003492,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Index date 2018
103,349,103003492,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Index date 2018
104,349,104003492,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Index date 2018
105,349,105003492,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Index date 2018
106,349,106003492,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Index date 2018
101,350,101003502,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Index date 2019
102,350,102003502,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Index date 2019
103,350,103003502,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Index date 2019
104,350,104003502,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Index date 2019
105,350,105003502,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Index date 2019
106,350,106003502,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Index date 2019
101,351,101003512,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Index date 2020
102,351,102003512,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Index date 2020
103,351,103003512,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Index date 2020
104,351,104003512,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Index date 2020
105,351,105003512,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Index date 2020
106,351,106003512,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Index date 2020
101,352,101003522,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Index year 2021
102,352,102003522,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Index year 2021
103,352,103003522,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Index year 2021
104,352,104003522,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Index year 2021
105,352,105003522,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Index year 2021
106,352,106003522,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Index year 2021
101,353,101003532,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without [PIONEER 2.0] Index year 2022
102,353,102003532,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without [PIONEER 2.0] Index year 2022
103,353,103003532,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without [PIONEER 2.0] Index year 2022
104,353,104003532,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without [PIONEER 2.0] Index year 2022
105,353,105003532,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without [PIONEER 2.0] Index year 2022
106,353,106003532,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without [PIONEER 2.0] Index year 2022
101,354,101003542,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
102,354,102003542,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
103,354,103003542,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
104,354,104003542,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
105,354,105003542,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
106,354,106003542,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT (LHRH or anti-androgen)
101,355,101003552,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
102,355,102003552,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
103,355,103003552,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
104,355,104003552,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
105,355,105003552,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
106,355,106003552,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT (Anti-androgen exclusive)
101,356,101003562,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
102,356,102003562,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
103,356,103003562,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
104,356,104003562,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
105,356,105003562,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
106,356,106003562,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT (LHRH exclusive)
101,357,101003572,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
102,357,102003572,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
103,357,103003572,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
104,357,104003572,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
105,357,105003572,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
106,357,106003572,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT (LHRH AND anti-androgens)
101,358,101003582,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA
102,358,102003582,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA
103,358,103003582,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA
104,358,104003582,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA
105,358,105003582,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA
106,358,106003582,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA
101,359,101003592,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
102,359,102003592,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
103,359,103003592,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
104,359,104003592,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
105,359,105003592,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
106,359,106003592,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (enzalutamide)
101,360,101003602,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
102,360,102003602,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
103,360,103003602,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
104,360,104003602,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
105,360,105003602,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
106,360,106003602,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (Abiraterone)
101,361,101003612,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
102,361,102003612,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
103,361,103003612,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
104,361,104003612,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
105,361,105003612,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
106,361,106003612,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (apalutamide)
101,362,101003622,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
102,362,102003622,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
103,362,103003622,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
104,362,104003622,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
105,362,105003622,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
106,362,106003622,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide)
101,363,101003632,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO
102,363,102003632,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO
103,363,103003632,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO
104,363,104003632,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO
105,363,105003632,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO
106,363,106003632,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO
101,364,101003642,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
102,364,102003642,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
103,364,103003642,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
104,364,104003642,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
105,364,105003642,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
106,364,106003642,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (docetaxel)
101,365,101003652,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
102,365,102003652,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
103,365,103003652,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
104,365,104003652,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
105,365,105003652,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
106,365,106003652,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Paclitaxel)
101,366,101003662,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
102,366,102003662,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
103,366,103003662,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
104,366,104003662,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
105,366,105003662,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
106,366,106003662,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + CHEMO (Cabazitaxel)
101,367,101003672,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
102,367,102003672,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
103,367,103003672,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
104,367,104003672,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
105,367,105003672,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
106,367,106003672,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA + CHEMO
101,368,101003682,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
102,368,102003682,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
103,368,103003682,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
104,368,104003682,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
105,368,105003682,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
106,368,106003682,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (darolutamide) + CHEMO (docetaxel)
101,369,101003692,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
102,369,102003692,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
103,369,103003692,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
104,369,104003692,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
105,369,105003692,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
106,369,106003692,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + ARTA (abiraterone) + CHEMO (docetaxel)
101,370,101003702,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + lutetium PSMA
102,370,102003702,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + lutetium PSMA
103,370,103003702,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + lutetium PSMA
104,370,104003702,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + lutetium PSMA
105,370,105003702,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + lutetium PSMA
106,370,106003702,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + lutetium PSMA
101,371,101003712,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT +Radium 223
102,371,102003712,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT +Radium 223
103,371,103003712,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT +Radium 223
104,371,104003712,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT +Radium 223
105,371,105003712,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT +Radium 223
106,371,106003712,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT +Radium 223
101,372,101003722,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
102,372,102003722,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
103,372,103003722,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
104,372,104003722,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
105,372,105003722,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
106,372,106003722,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT +PARP Inhibitor
101,373,101003732,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + olaparib
102,373,102003732,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + olaparib
103,373,103003732,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + olaparib
104,373,104003732,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + olaparib
105,373,105003732,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + olaparib
106,373,106003732,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + olaparib
101,374,101003742,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + rucaparib
102,374,102003742,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + rucaparib
103,374,103003742,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + rucaparib
104,374,104003742,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + rucaparib
105,374,105003742,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + rucaparib
106,374,106003742,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + rucaparib
101,375,101003752,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + immunotherapy
102,375,102003752,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + immunotherapy
103,375,103003752,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + immunotherapy
104,375,104003752,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + immunotherapy
105,375,105003752,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + immunotherapy
106,375,106003752,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + immunotherapy
101,376,101003762,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + sipuleucel-T
102,376,102003762,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + sipuleucel-T
103,376,103003762,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + sipuleucel-T
104,376,104003762,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + sipuleucel-T
105,376,105003762,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + sipuleucel-T
106,376,106003762,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + sipuleucel-T
101,377,101003772,TwoS,[PIONEER 2.0] Target Cohort 1.0_ mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + pembrolizumab
102,377,102003772,TwoS,[PIONEER 2.0] Target Cohort 1.1_mHSPC (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + pembrolizumab
103,377,103003772,TwoS,[PIONEER 2.0] Target Cohort 1.2_metachronous mHSPC FINAL without REVIEW [PIONEER 2.0] ADT + pembrolizumab
104,377,104003772,TwoS,[PIONEER 2.0] Target Cohort 2.0_mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + pembrolizumab
105,377,105003772,TwoS,[PIONEER 2.0] Target Cohort 2.1_mHSPC treated (synchronous) FINAL without REVIEW [PIONEER 2.0] ADT + pembrolizumab
106,377,106003772,TwoS,[PIONEER 2.0] Target Cohort 2.2_metachronous mHSPC treated FINAL without REVIEW [PIONEER 2.0] ADT + pembrolizumab
